Abstract: Aspects of the invention include methods for applying to a subject a transdermal delivery device configured to deliver a non-sedative amount of a dexmedetomidine composition. In practicing methods according to certain embodiments, a non-sedative amount of a dexmedetomidine composition is transdermally applied to a subject and is maintained in contact with the subject in a manner sufficient to deliver a non-sedative amount of dexmedetomidine to a subject. Also provided are transdermal delivery devices having a non-sedative amount of dexmedetomidine sufficient for practicing the subject methods, as well as kits containing the transdermal delivery devices.
Abstract: Provide is a method of using a topoisomerase I inhibitor in treatment of cancer to reduce bone marrow suppression. The method includes administering to a subject in need thereof an effective amount of a pharmaceutical composition. The composition has at least one hydrophobic topoisomerase I inhibitor or a pharmaceutically acceptable salt thereof, and at least one polyethylene glycol (PEG) conjugated phospholipid, wherein the molar ratio of said PEG conjugated phospholipid to said hydrophobic topoisomerase I inhibitor or said pharmaceutically acceptable salt of said hydrophobic topoisomerase I inhibitor is about 0.45:1 to about 1.05:1.
Type:
Grant
Filed:
July 3, 2019
Date of Patent:
April 20, 2021
Assignees:
TAIWAN LIPOSOME COMPANY, LTD., TLC BIOPHARMACEUTICALS, INC.
Abstract: Methods for the treatment of stroke, such as stroke of undetermined origin, by administration of xenon (Xe)-loaded liposome compositions are provided. In some aspects, Xe is encapsulated in echogenic liposomes and release of Xe can be enhanced by application of ultrasound stimulation. Compositions for use in treating stroke, such as liposomes loaded with Xe or Xe in combination with H2 or H2S, are also provided.
Type:
Grant
Filed:
June 26, 2019
Date of Patent:
April 13, 2021
Assignee:
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
Inventors:
Shao-Ling Huang, Melvin E. Klegerman, Yong-Jian Geng, Hyunggun Kim, David D. Mcpherson
Abstract: The invention provides a particulate composition adapted for forming a bone graft substitute cement upon mixing with an aqueous solution, comprising i) a calcium sulfate hemihydrate powder, wherein the calcium sulfate hemihydrate is present at a concentration of at least about 50 weight percent based on the total weight of the particulate composition; ii) a monocalcium phosphate monohydrate powder; iii) a non-porous ?-tricalcium phosphate powder; and iv) a porous ?-tricalcium phosphate powder. Bone graft substitute cements made therefrom, a bone graft substitute kit comprising the particulate composition, methods of making and using the particulate composition, and articles made from the bone graft substitute cement are also provided.
Type:
Grant
Filed:
August 16, 2016
Date of Patent:
April 13, 2021
Assignee:
Agnovos Healthcare, LLC
Inventors:
Jon P. Moseley, Jamie MacDougall, Katie Harrigan
Abstract: The disclosed are shelf-stable beta-hydroxyisovaleric acid containing soft gel compositions and methods for making such compositions. In certain aspects, disclosed compositions comprise a plant-based capsule shell and a liquid formulation comprising beta-hydroxyisovaleric acid and at least one excipient, wherein the soft gel capsule is shelf-stable. In certain aspects, the excipient is selected from selected from choline salt, betaine, phosphatidylcholine, alpha-glycerophosphocholine, carnitine, adenosine 5?-triphosphate, or a combination thereof.
Type:
Grant
Filed:
May 25, 2017
Date of Patent:
March 30, 2021
Assignee:
TSI Group Ltd.
Inventors:
Martin Purpura, Ralf Jager, Jie Gu, Xiong Zheng, Iingwei Dai, Yaohua Zhang
Abstract: An anti-microbial formulation for seed and crop application includes about 170 ppm hypochlorous acid; about 25 ppm hypochlorite ion; about 2.5 ppm ozone; about 2.5 ppm chlorine dioxide; between about 10 ppm and about 100,000 ppm alkyl polyglycoside; and a remainder of water. A method of manipulating the pH of the formulation and a method of treating seeds and crops with the formulation to restrict or eliminate microbial growth and proliferation is also described herein.
Abstract: A material for adhesion prevention can be adhered to biological tissue with certainty and has improved tissue adhesiveness and biodegradability. Such material for adhesion prevention is composed of: a 1- to 1,000-?m-thick water-soluble support layer comprising a water-soluble polymer; and a 1- to 1,000-?m-thick adhesion prevention layer comprising a biodegradable polymer. The biodegradable polymer has a structure in which a branched polyalkylene glycol comprising 3 to 8 terminal hydroxyl groups per molecule is bound to a polyhydroxy alkanoic acid, and a mass ratio of the branched polyalkylene glycol relative to the total mass is 1% to 30%.
Abstract: The present invention relates to nanoparticles for encapsulating biologically active compounds, comprising a matrix of new polymer conjugates. The invention also relates to a process for producing both the conjugates and nanoparticles, to compositions containing said conjugates or nanoparticles, and applications thereof. The invention is applicable in the pharmaceutical sector and in the nanotechnology sector.
Type:
Grant
Filed:
November 30, 2015
Date of Patent:
March 2, 2021
Assignee:
INNOUP FARMA, S.L.
Inventors:
Juan Manuel Irache Garreta, Judit Huarte Ciganda, Laura Inchaurraga Casadamón, Luisa Fernanda Ruiz Gatón, Nekane Martín Arbellá
Abstract: Oral care compositions and/or unit-dose oral care compositions with a fluoride ion source. Oral care compositions and/or unit-dose oral care compositions with a high average fluoride ion uptake. Oral care compositions with one or more web forming materials, a calcium ion source, and a fluoride ion source with a high average fluoride uptake.
Type:
Grant
Filed:
May 14, 2019
Date of Patent:
March 2, 2021
Assignee:
The Procter & Gamble Company
Inventors:
Arif Ali Baig, Min Mao, Gregory Charles Gordon, Melissa Cherie Payne, Holly Balasubramanian Rauckhorst, Paul Albert Sagel, Jeanette Marie Swartz, Paul Dennis Trokhan, Brian Patrick Croll, Dinah Achola Nyangiro, Samuel James St. John
Abstract: A toothpaste composition having a plant oil constituent together with white or a close shade of white coconut shell activated charcoal constituent is disclosed herein.
Abstract: This application provides, among other things, novel aqueous biphasic oral care compositions comprising two distinct aqueous phases, useful for combining and delivering poorly compatible ingredients, for example to deliver effective levels of cationic antibacterial agents in combination with anionic polymers, e.g. that protect against erosion and staining, by addition of a stabilizing amount of a polyamine, e.g. lysine, and methods for making and using the same.
Type:
Grant
Filed:
August 4, 2017
Date of Patent:
February 9, 2021
Assignee:
Colgate-Palmolive Company
Inventors:
Carl Myers, Rehana Begum-Gafur, Jeffrey Merl Miller, Ekta Makwana
Abstract: A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.
Type:
Grant
Filed:
May 5, 2017
Date of Patent:
January 26, 2021
Assignee:
LIQUIDIA TECHNOLOGIES, INC.
Inventors:
Robert Frank Roscigno, Brian T. Farrer, Jacob J. Sprague, Benjamin Maynor
Abstract: The present invention relates to fumarate polymersomes. The polymersomes are capable of targeting immune cells and then hydrolysing to release the immunomodulatory compound fumarate. The polymersomes can thus be used methods for the treatment of prevention of diseases, including immune diseases such as multiple sclerosis and psoriasis.
Abstract: A composition includes sintered ferrous amino acid particles prepared by sintering a ferrous amino acid chelate which includes ferrous ions and an amino acid. The sintered ferrous amino acid particles have an average particle size ranging from 500 to 2600 nm and a weight average molecular weight ranging from 1,500 Dalton to 600,000 Dalton. Also disclosed herein are a method for inhibiting and/or killing a virus in a subject and applications of such method. The method includes administering to the subject the composition.
Type:
Grant
Filed:
July 31, 2019
Date of Patent:
January 5, 2021
Assignee:
PROFEAT BIOTECHNOLOGY CO., LTD.
Inventors:
Tsun-Yuan Lin, Mu-Kuei Chen, Kai-Ting Wang, Hsun-Jin Jan
Abstract: Described herein are pharmaceutical compositions for the oral administration of mesalazine, as well as methods of making such pharmaceutical compositions, and therapeutic methods for using them. The compositions comprise delayed-immediate release and delayed-extended release formulation of mesalazine.
Type:
Grant
Filed:
April 18, 2017
Date of Patent:
December 29, 2020
Assignee:
FERRING B.V.
Inventors:
Alfred Chi Yeh Liang, Venkataramana Dingari
Abstract: A delivery system comprising hydrogen peroxide or a hydrogen peroxide generator system, for use in a method for the treatment or prevention of inflammatory bowel disease in a mammal, is described. The method comprises a step of orally administering to the mammal the delivery system, wherein the delivery system is formulated for oral delivery and release of the hydrogen peroxide or hydrogen peroxide generator system in-situ at a target location in the mammalian gastrointestinal tract. Also described is an oral dosage delivery system comprising hydrogen peroxide or a hydrogen peroxide generator system, in which the delivery system is configured for oral administration to a mammal and release of the hydrogen peroxide or hydrogen peroxide generator system at a target location within the mammalian gastrointestinal tract thereby effecting a localised increase in hydrogen peroxide levels at the target location in the mammalian gut or airways.
Type:
Grant
Filed:
April 6, 2017
Date of Patent:
December 22, 2020
Assignee:
University College Dublin, National University of Ireland, Dublin
Abstract: Disclosed are conjugated polymer nanoparticles and a method of producing the same. The conjugated polymer nanoparticles include a conjugated polymer, fatty acid and an amphiphile polymer. The conjugated polymer nanoparticles can be doped even under a neutral environment, thus exhibiting high electrical conductivity and exerting absorbance properties in the near-infrared band even under a neutral environment such as in vivo.
Type:
Grant
Filed:
March 19, 2015
Date of Patent:
December 15, 2020
Assignee:
Industry-Academic Cooperation Foundation, Yonsei University
Inventors:
Jae Moon Yang, Jung Hyun Kim, Jeong Hun Kim, Yoo Chan Hong, Won Seok Cho, Seung Yeon Hwang, Jin Suck Suh
Abstract: The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).
Type:
Grant
Filed:
April 18, 2019
Date of Patent:
December 1, 2020
Assignee:
SPRUCE BIOSCIENCES, INC.
Inventors:
Alexis Howerton, Hal Gerber, Michael Huang